130 related articles for article (PubMed ID: 24738551)
1. Parenteral patent drug S/GSK1265744 has the potential to be an effective agent in pre-exposure prophylaxis against HIV infection.
Taha H; Morgan J; Das A; Das S
Recent Pat Antiinfect Drug Discov; 2013 Dec; 8(3):213-8. PubMed ID: 24738551
[TBL] [Abstract][Full Text] [Related]
2. A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor.
Kovač L; Časar Z
Expert Opin Ther Pat; 2020 Mar; 30(3):195-208. PubMed ID: 31944142
[No Abstract] [Full Text] [Related]
3. Long-acting Cabotegravir Shot Prevents HIV Among Women.
Abbasi J
JAMA; 2020 Dec; 324(22):2247. PubMed ID: 33289810
[No Abstract] [Full Text] [Related]
4. Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?
Brooks KM; Sherman EM; Egelund EF; Brotherton A; Durham S; Badowski ME; Cluck DB
Pharmacotherapy; 2019 May; 39(5):576-598. PubMed ID: 30860610
[TBL] [Abstract][Full Text] [Related]
5. Considerations for Implementing Cabotegravir (Apretude) as PrEP for HIV Infection.
Zimmerman H; Vogl A
Am Fam Physician; 2024 Apr; 109(4):296. PubMed ID: 38648820
[No Abstract] [Full Text] [Related]
6. Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis.
Stellbrink HJ; Hoffmann C
Curr Opin HIV AIDS; 2018 Jul; 13(4):334-340. PubMed ID: 29746267
[TBL] [Abstract][Full Text] [Related]
7. Cabotegravir (Apretude) for HIV-1 pre-exposure prophylaxis.
Med Lett Drugs Ther; 2022 Feb; 64(1644):29-31. PubMed ID: 35171897
[No Abstract] [Full Text] [Related]
8. Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in rat.
Jucker BM; Alsaid H; Rambo M; Lenhard SC; Hoang B; Xie F; Groseclose MR; Castellino S; Damian V; Bowers G; Gupta M
J Control Release; 2017 Dec; 268():102-112. PubMed ID: 29042321
[TBL] [Abstract][Full Text] [Related]
9. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.
Andrews CD; Spreen WR; Mohri H; Moss L; Ford S; Gettie A; Russell-Lodrigue K; Bohm RP; Cheng-Mayer C; Hong Z; Markowitz M; Ho DD
Science; 2014 Mar; 343(6175):1151-4. PubMed ID: 24594934
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
[TBL] [Abstract][Full Text] [Related]
11. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
Özdener AE; Park TE; Kalabalik J; Gupta R
Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
[TBL] [Abstract][Full Text] [Related]
12. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
Murray MI; Markowitz M; Frank I; Grant RM; Mayer KH; Hudson KJ; Stancil BS; Ford SL; Patel P; Rinehart AR; Spreen WR; Margolis DA
HIV Clin Trials; 2018 Aug; 19(4):129-138. PubMed ID: 30445896
[TBL] [Abstract][Full Text] [Related]
13. New first and second generation inhibitors of human immunodeficiency virus-1 integrase.
Pendri A; Meanwell NA; Peese KM; Walker MA
Expert Opin Ther Pat; 2011 Aug; 21(8):1173-89. PubMed ID: 21599420
[TBL] [Abstract][Full Text] [Related]
14. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251.
Andrews CD; Bernard LS; Poon AY; Mohri H; Gettie N; Spreen WR; Gettie A; Russell-Lodrigue K; Blanchard J; Hong Z; Ho DD; Markowitz M
AIDS; 2017 Feb; 31(4):461-467. PubMed ID: 27902508
[TBL] [Abstract][Full Text] [Related]
15. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
[TBL] [Abstract][Full Text] [Related]
16. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
[TBL] [Abstract][Full Text] [Related]
17. Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1.
McPherson TD; Sobieszczyk ME; Markowitz M
Expert Opin Investig Drugs; 2018 Apr; 27(4):413-420. PubMed ID: 29633869
[TBL] [Abstract][Full Text] [Related]
18. Long-acting injectable for HIV approved for use in the UK.
Kirby T
Lancet Infect Dis; 2022 Jan; 22(1):26. PubMed ID: 34953553
[No Abstract] [Full Text] [Related]
19. Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor.
Cattaneo D; Gervasoni C
Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):319-327. PubMed ID: 30387005
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention.
Yap PK; Loo Xin GL; Tan YY; Chellian J; Gupta G; Liew YK; Collet T; Dua K; Chellappan DK
J Pharm Pharmacol; 2019 Sep; 71(9):1339-1352. PubMed ID: 31144296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
